Table 3.

Survival times and progression times between cTACE and DEB-TACE treatments

Variables	cTACE	DEB-TACE	p-value
Total	(n = 201)	(n = 72)
Survival status			0.045
Died within ≤5 years follow-up	153 (76.1)	48 (66.7)
Died after more than 5 years follow-up	10 (5.0)	1 (1.4)
Survived until last follow-up	38 (18.9)	23 (31.9)
Progression status			0.218
Progression	192 (95.5)	66 (91.7)
Loss of follow-up/censored	9 (4.5)	6 (8.3)
Survival time, months	37 (32.2, 41.8)	37 (23.5, 50.5)	0.091
Progression time, months	11.0 (9.6, 12.4)	16.0 (13.1, 18.9)	0.019
BCLC stage = A	(n = 73)	(n = 16)
Survival status			0.083
Died within ≤5 years follow-up	57 (78.1)	9 (56.3)
Died after more than 5 years follow-up	3 (4.1)	0 (0)
Survived until last follow-up	13 (17.8)	7 (43.8)
Progression status			0.219
Progression	70 (95.9)	14 (87.5)
Loss of follow-up/censored	3 (4.1)	2 (12.5)
Survival time, months	42 (36.1, 47.9)	45 (0, 90.1)	0.149
Progression time, months	12 (10.5, 13.5)	19 (17.8, 20.2)	0.217
BCLC stage = B + C	(n = 128)	(n = 56)
Survival status			0.270
Died within ≤5 years follow-up	96 (75)	39 (69.6)
Died after more than 5 years follow-up	7 (5.5)	1 (1.8)
Survived until last follow-up	25 (19.5)	16 (28.6)
Progression status			0.495
Progression	122 (95.3)	52 (92.9)
Loss of follow-up/censored	6 (4.7)	4 (7.1)
Survival time, months	33 (27.1, 38.9)	36 (21.3, 50.7)	0.191
Progression time, months	10 (8.1, 11.9)	15 (12.4, 17.7)	0.032

Survival and progression status are summarized as n (%) by treatment; Survival time- and progression time-related data are summarized as median (95%CI) by treatment

Differences between treatments were compared using Pearson Chi-square test / or Fisher’s exact test for survival and progression status and Log-rank test for survival time or progression time

Bold p-values indicate statistical significance (p < 0.05)